Filing Flows › China Pharma Holdings (CPHI) › Q4 2025
China Pharma Holdings (CPHI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Apr 1, 2026
China Pharma Holdings (CPHI) reported revenue of $1.2M for the fourth quarter 2025 (Q4 2025), +8% from a year earlier and +62% from the quarter before. Operating margin was -97.9%, net loss $1.2M (99.7% of revenue).
China Pharma Holdings, Q4 2025: revenue $1.2M (+8% year over year), operating margin -97.9%, net loss $1.2M, operating cash flow $152K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | +62% | +8% |
| Operating profit | −$1.2M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | $152K | — | -49% |
| Free cash flow | $152K | — | -46% |
What changed
Revenue was $1.2M in Q4 2025, up 8% year over year and up 62% from the previous quarter.
Gross margin was 12.3%. Operating costs exceeded revenue by $1.2M, an operating margin of -97.9%. The quarter ended with a net loss of $1.2M, wider than the previous quarter's $651K loss.
Operating cash flow was $152K (down 49% year over year). Non-cash charges added back $497K of depreciation and amortization. Working capital and other items added $877K. Capital expenditures of $0K left free cash flow of $152K.
Questions
What was China Pharma Holdings' revenue in the fourth quarter 2025?
China Pharma Holdings (CPHI) reported revenue of $1.2M for the fourth quarter 2025 (Q4 2025), +8% from a year earlier and +62% from the quarter before.
Was China Pharma Holdings profitable in the fourth quarter 2025?
Operating loss was $1.2M (-97.9% of revenue) and net loss $1.2M.